Lavi Erisson
Chief Executive Officer Gensaic
Lavi Erisson is the CEO and Cofounder of Gensaic, a pioneering genomics medicines company. A seasoned entrepreneur and leader, Lavi brings a unique blend of scientific, strategic, and business expertise to the forefront of biotechnology. His career includes nearly a decade in corporate venture and translational medicine at Teva Pharmaceuticals, followed by key leadership roles, including Chief Business & Medical Officer at Iterative Scopes. He is also an MIT Sloan Fellow, where his research focused on machine learning in health and novel drug delivery platforms. Lavi is dedicated to advancing cutting-edge science into transformative therapies for patients.
Seminars
The RNAi therapeutics landscape is rapidly evolving, with breakthroughs in delivery, efficacy, and commercialization reshaping investor expectations. Key discussion points will include clinical differentiation, market potential, and exit strategies, offering a reality check on valuation drivers and red flags.
- Prioritizing delivery platform versatility as a key value driver, enabling investors to back RNAi companies with broad therapeutic applicability
- Assessing clinical milestones beyond knockdown efficiency, including durability and patient-centric endpoints, to identify therapies with superior commercial potential
- Balancing platform validation with indication selection for optimal risk/reward, ensuring portfolio companies can attract pharma partnerships or IPO success
